The ENBALV trial showed that Edoxaban, a direct oral anticoagulant, was as effective as or more effective than warfarin in preventing thromboembolism after bioprosthetic valve replacement surgery. The study involved 410 participants who were randomly assigned to either Edoxaban or warfarin for 12 weeks. Results showed a lower primary outcome event rate in the Edoxaban group, although bleeding risks were higher. However, the event rate was so low that definitive conclusions could not be reached. The study suggests that Edoxaban could be an alternative to warfarin for low-risk patients post-surgery, but improved patient stratification is needed to assess who is at risk for stroke and systemic embolism.
Source link
Anticoagulant Considered After Bioprosthetic Valve Surgery
